成纤维细胞激活蛋白靶向18F-FAPI-74 PET/CT评估胃肠道肿瘤:与18F-FDG PET/CT的比较
前瞻性研究纳入112例确诊胃、肝或胰腺恶性肿瘤患者,于2022年6月至12月同期行18F-FDG与18F-FAPI-74 PET/CT。结果显示18F-FAPI-74 PET/CT在检测原发肿瘤、局部复发、受累淋巴结及骨和内脏转移方面敏感性优于18F-FDG,并使17例初治患者TNM分期上调、4例复发/转移患者临床管理改变。
要点
- 18F-FAPI-74 PET/CT检测原发胃癌敏感性88%高于18F-FDG的60%,差异有统计学意义。
- 18F-FAPI-74检测骨和内脏转移敏感性98%高于18F-FDG的47%,差异有统计学意义。
- 18F-FAPI-74使17/69例初治患者TNM分期上调、4/43例复发患者管理改变。
核心结论
- 在胃癌、胰腺癌和肝癌中,18F-FAPI-74 PET/CT在检测原发肿瘤、局部复发、淋巴结受累及骨和内脏转移方面优于18F-FDG PET/CT,且多数原发和转移病灶摄取更高。
研究设计与样本
- 前瞻性研究分析2022年6月至2022年12月间确诊胃、肝或胰腺恶性肿瘤并同期接受18F-FDG和18F-FAPI-74 PET/CT的患者。
- 共纳入112例患者:胃癌49例、肝癌39例、胰腺癌24例;69例用于初始分期,43例用于复发检测。
- PET/CT所见由组织病理学或影像学随访确认,采用Wilcoxon符号秩检验比较摄取和靶本比,McNemar检验比较两种扫描的诊断准确性。
主要发现
- 基于病灶的诊断准确性:原发胃癌敏感性18F-FAPI-74组88%(22/25)vs 18F-FDG组60%(15/25),P=0.016。
- 原发肝癌敏感性18F-FAPI-74组100%(22/22)vs 18F-FDG组82%(18/22),P=0.125;原发胰腺癌敏感性18F-FAPI-74组100%(22/22)vs 18F-FDG组86%(19/22),P=0.250。
- 局部复发敏感性18F-FAPI-74组92%(23/25)vs 18F-FDG组56%(14/25),P=0.021。
- 受累淋巴结敏感性18F-FAPI-74组71%(41/58)vs 18F-FDG组40%(23/58),P<0.001;骨和内脏转移敏感性18F-FAPI-74组98%(350/358)vs 18F-FDG组47%(168/358),P<0.001。
- 与18F-FDG相比,18F-FAPI-74 PET/CT使全部初治患者中17例(17/69,25%)TNM分期上调,并使检测到复发或转移的43例患者中4例(4/43,9%)临床管理改变。
关键数值与推荐
- 原发肿瘤敏感性:胃癌18F-FAPI-74组88%(22/25)vs 18F-FDG组60%(15/25),P=0.016;肝癌18F-FAPI-74组100%(22/22)vs 18F-FDG组82%(18/22),P=0.125;胰腺癌18F-FAPI-74组100%(22/22)vs 18F-FDG组86%(19/22),P=0.250。
- 局部复发敏感性18F-FAPI-74组92%(23/25)vs 18F-FDG组56%(14/25),P=0.021。
- 受累淋巴结敏感性18F-FAPI-74组71%(41/58)vs 18F-FDG组40%(23/58),P<0.001。
- 骨和内脏转移敏感性18F-FAPI-74组98%(350/358)vs 18F-FDG组47%(168/358),P<0.001。
- 分期与管理改变:初治患者中17/69(25%)TNM分期上调;复发或转移患者中4/43(9%)临床管理改变。
临床怎么用
- 原文结论指出18F-FAPI-74 PET/CT在胃癌、胰腺癌和肝癌的原发肿瘤、局部复发、淋巴结受累及骨和内脏转移检测方面优于18F-FDG PET/CT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein is overexpressed in the stroma of several cancer types. 18F-fibroblast activation protein inhibitor (FAPI)-74 is a PET tracer with high selectivity for fibroblast activation protein and has shown high accumulation in human tumors in clinical studies. However, the use of 18F-FAPI-74 for PET imaging of gastrointestinal cancer has not been systematically investigated. Herein, we investigated the diagnostic accuracy of 18F-FAPI-74 (18F-LNC1005) PET/CT in gastric, liver, and pancreatic cancers and compared the results with those of 18F-FDG PET/CT. Methods: This prospective study analyzed patients with confirmed gastric, liver, or pancreatic malignancies who underwent concurrent 18F-FDG and 18F-FAPI-74 PET/CT between June 2022 and December 2022. PET/CT findings were confirmed by histopathology or radiographic follow-up. 18F-FDG and 18F-FAPI-74 uptake and tumor-to-background ratios were compared using the Wilcoxon signed-rank test. The McNemar test was used to compare the diagnostic accuracy of the 2 scans. Results: Our cohort consisted of 112 patients: 49 with gastric cancer, 39 with liver cancer, and 24 with pancreatic cancer. Among them, 69 patients underwent PET/CT for initial staging and 43 for recurrence detection. Regarding lesion-based diagnostic accuracy, 18F-FAPI-74 PET/CT showed higher sensitivity than did 18F-FDG in the detection of primary tumors (gastric cancer, 88% [22/25] vs. 60% [15/25], P = 0.016; liver cancer, 100% [22/22] vs. 82% [18/22], P = 0.125; pancreatic cancer, 100% [22/22] vs. 86% [19/22], P = 0.250), local recurrence (92% [23/25] vs. 56% [14/25]; P = 0.021), involved lymph nodes (71% [41/58] vs. 40% [23/58]; P < 0.001), and bone and visceral metastases (98% [350/358] vs. 47% [168/358]; P < 0.001). Compared with 18F-FDG, 18F-FAPI-74 PET/CT upstaged 17 patients' TNM staging among all treatment-naïve patients (17/69, 25%) and changed the clinical management of 4 patients (4/43, 9%) in whom recurrence or metastases were detected. Conclusion: 18F-FAPI-74 PET/CT is superior to 18F-FDG PET/CT in detecting primary tumors, local recurrence, lymph node involvement, and bone and visceral metastases in gastric, pancreatic, and liver cancers, with higher uptake in most primary and metastatic lesions.
引用
- Xu W, Cai J, Peng T, et al. Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT. J Nucl Med. 2024. PMID: 37884330. doi:10.2967/jnumed.123.266329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。